Competitive GLP-1 antagonist Exendin (9 − 3) has been shown to normalize the exaggerated insulin secretion after MMT and to prevent hypoglycemia during MMT [8] and during oral glucose tolerance test (OGTT) [10]. This evidence concerns the gene GLP1R and Hypoglycemia.